New drugs and novel targets for treatment of invasive fungal infections in patients with cancer

Oncologist

Volumn 5, Issue 2, 2000, Pages 120-135

  Chiou, Christine C ^a   Groll, Andreas H ^a   Walsh, Thomas J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Echinocondins; Posaconazole; Ravuconazole; Triazoles; Voriconazole

Indexed keywords

ALLYLAMINE; AMPHOTERICIN B; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; FLUCYTOSINE; GRISEOFULVIN; ITRACONAZOLE; KETOCONAZOLE; MICAFUNGIN; NIKKOMYCIN Z; NUCLEOSIDE ANALOG; POLYENE ANTIBIOTIC AGENT; POSACONAZOLE; PYRROLE; RAVUCONAZOLE; SORDARIN; TERBINAFINE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; CANCER INVASION; CANCER PATIENT; CANDIDA ALBICANS; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; HIGH RISK POPULATION; HUMAN; MYCOSIS; PRIORITY JOURNAL; TARGET CELL; TISSUE DISTRIBUTION;

EID: 0034093263     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.5-2-120     Document Type: Article

References (150)

1. Groll AH, Shah PM, Mentzel C et al. Trends in the post-mortem epidemiology of invasive fungal infections at a university hospital. J Infect 1996;33:23-32.
2. Walsh TJ, Hiemenz JW, Anaissie E. Recent progress and current problems in treatment of invasive fungal infections in neutropenic patients. Infect Dis Clin North Am 1996;10:365-400.
3. Walsh TJ, Hiemenz J, Pizzo PA. Evolving risk factors for invasive fungal infections: all neutropenic patients are not the same. Clin Infec Dis 1994;18:793-798.
4. Walsh TJ, Gonzalez C, Lyman CA et al. Invasive fungal infections in children: recent advances in diagnosis and treatment. Adv Pediatr Infect Dis 1996;11:187-290.
5. Anaissie E. Opportunistic mycoses in the immunocompromised host: experience at a cancer center and review. Clin Infec Dis 1992;(suppl 1):S43-S53.
6. Armstrong D. Problems in management of opportunistic fungal infections. Rev Infect Dis 1989;(suppl 7):S1591-S1599.
7. Pfaller MA, Wenzel R. The impact of changing epidemiology of fungal infections in the 1990s. Eur J Clin Microbiol Infect Dis 1992;11:287-291.
8. Richardson MD. Opportunistic and pathogenic fungi. Antimicrob Agents Chemother 1991;28(suppl A):1-11.
9. Walsh TJ. Invasive fungal infections: problems and challenges in developing new antifungal compounds. In: Sutcliffe J, Georgopapadakou NH, eds. Emerging Targets in Antibacterial and Antifungal Chemotherapy. New York: Chapman & Hall, 1992:349-373.
10. Wong-Beringer A, Jacobs RA, Guglielmo BJ. Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin Infect Dis 1998;27:603-618.
11. Janknergt R, vanEtten EWM, de Marie S. Lipid formulations of amphotericin B. Curr Opin Infect Dis 1996;9:403-406.
12. Hiemenz JW, Walsh TJ. Lipid formulations of amphotericin B: recent progress and future decisions. Clin Infect Dis 1996; 22(suppl 2):S133-S144.
13. Akova M, Akalin HE, Uzun O et al. Efficacy of fluconazole in the treatment of upper gastrointestinal candidiasis in neutropenic patients with cancer: factors influencing the outcome. Clin Infect Dis 1994;18:298-301.
14. Rex JH, Bennett JE, Sugar AM et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 1994;331:1325-1330.
15. Edwards JE Jr, Bodey GP, Bowden RA et al. International conference for the development of a consensus on the management and prevention of severe candidal infections. Clin Infect Dis 1997;25:43-59.
16. Phillips P, Shafran S, Garber G et al. Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Eur J Clin Microbiol Infect Dis 1997;16:337-345.
17. Anaissie EJ, Darouiche RO, Abi-Said D et al. Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin Infect Dis 1996;23:964-972.
18. Anaissie EJ, Vartivarian SE, Abi-Said D et al. Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study. Am J Med 1996;101:170-176.
19. Anaissie E, Bodey GP, Kantarjian H et al. Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy. Am J Med 1991;91:142-150.
20. Kauffman CA, Bradley SF, Ross SC et al. Hepatosplenic candidiasis: successful treatment with fluconazole. Am J Med 1991;91:137-141.
21. Anaissie EJ, Kontoyiannis DP, Huls C et al. Safety, plasma concentrations, and safety of high-dose fluconazole in invasive mold infection. J Infect Dis 1995;172:599-602.
22. Marr KA, White TC, vanBurik JAH et al. Development of fluconazole resistance in Candida albicans causing disseminated infection in a patient undergoing marrow transplantation. Clin Infect Dis 1997;25:908-910.
23. Mori T, Matsumura M, Kanamaru Y et al. Myelofibrosis complicated by infection due to Candida albicans: emergence of resistance to agents during therapy. Clin Infect Dis 1997;25:2470-2471.
24. Nolte FS, Parkinson T, Falconer DJ et al. Isolation and characterization of fluconazole- and amphotericin B-resistant Candida albicans from blood of two patients with leukemia. Antimicrob Agents Chemother 1997;41:196-199.
25. Groll AH, Walsh TJ. Azoles: triazoles. In: Yu VL, Merigan TC Jr, Barriere SL, eds. Antimicrobial Therapy and Vaccines. Baltimore, MD: Williams & Wilkins, 1998:1158-1169.
26. Denning DW, Lee JY, Hostetler JS et al. NIAID Mycoses Study Group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am J Med 1994;97:135-144.
27. White MH, Anaissie EJ, Kusne S et al. Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis. Clin Infect Dis 1997;24:635-642.
28. Bradford CR, Prentice AG, Warnock DW et al. Comparison of the multiple dose pharmacokinetics of itraconazole during remission induction for acute myeloblastic leukemia. J Antimicrob Chemother 1991;28:555-560.
29. Persat F, Marzullo C, Guyotat D et al. Plasma itraconazole concentrations in neutropenic patients after repeated high-dose treatment. Eur J Cancer 1992;28A:838-841.
30. Denning DW, Radford SA, Oakley KL et al. Correlation between in-vitro susceptibility testing to itraconazole and invivo outcome of Aspergillus fumigatus infection. J Antimicrob Chemother 1997;40:401-414.
31. Groll AH, Piscitelli SC, Walsh TJ. Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv Pharmacol 1998;44:343-500.
32. Barry AL, Brown SD. In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species. Antimicrob Agents Chemother 1996;40:1948-1949.
33. Macro F, Pfaller MA, Messer S et al. In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp. Antimicrob Agents Chemother 1998;42:161-163.
34. Pfaller MA, Messer SA, Hollis RJ et al. In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole. Antimicrob Agents Chemother 1998;42:3242-3244.
35. Clancy CJ, Nguyen MH. In vitro efficacy and fungicidal activity of voriconazole against Aspergillus and Fusarium species. Eur J Clin Microbiol Infect Dis 1998;17:573-575.
36. Murphy ME, Bernard M, Ishimaru T et al. Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 1997;41:696-698.
37. Nguyen MH, Yu CY. Voriconazole against fluconazole-susceptible and resistant Candida isolates: in-vitro efficacy compared with that of itraconazole and ketoconazole. J Antimicrob Chemother 1998;42:253-256.
38. McGinnis MR, Pasarell L, Sutton DA et al. In vitro activity of voriconazole against selected fungi. Med Mycol 1998;36:239-242.
39. Radford SA, Johnson EM, Warnock DW. In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens. Antimicrob Agents Chemother 1997;41:841-843.
40. Ruhnke M, Schmidt-Westhausen A, Trautmann M. In vitro activities of voriconazole (UK-109,486) against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection. Antimicrob Agents Chemother 1997;41:575-577.
41. Nguyen MH, Yu CY. In vitro comparative efficacy of voriconazole and itraconazole against fluconazole-susceptible and resistant Cryptococcus neoformans isolates. Antimicrob Agents Chemother 1998;42:471-472.
42. Macro F, Pfaller MA, Messer SA et al. Antifungal activity of a new triazole, voriconazole (UK-109-496), compared with three other antifungal agents tested against clinical isolates of filamentous fungi. Med Mycol 1998;36:433-436.
43. Wildfeuer A, Seidl HP, Paule I et al. In vitro evaluation of voriconazole against clinical isolates of yeasts, moulds and dermatophytes in comparison with itraconazole, ketoconazole, amphotericin B and griseofulvin. Mycoses 1998;41:309-319.
44. Troke PF, Brammer KW, Hitchcock CA et al. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: activity in systemic candidiasis models and early clinical efficacy in oropharyngeal candidiasis (OPC). In: Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1995:125.
45. Hitchcock CA, Andrews BJ, Lewis BGH et al. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: antifungal activity in experimental infections with Aspergillus. In: Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1995:125.
46. George D, Miniter P, Andriole VT. Efficacy of UK-109496, a new triazole antifungal agent, in an experimental model of invasive aspergillosis. Antimicrob Agents Chemother 1996;40:86-91.
47. Sheehan DJ, Hitchcock CA, Sibley C. Current and emerging azole antifungal agents. Clin Microbiol Rev 1999;12:40-79.
48. Martin MV, Yates J, Hitchcock CA. Comparison of voriconazole (UK-109,496) and itraconazole in prevention and treatment of Aspergillus fumigatus endocarditis in guinea pigs. Antimicrob Agents Chemother 1997;41:13-16.
49. Hitchcock CA, Andrews BJ, Lewis BGH et al. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: antifungal activity in experimental infections with cryptococcus. In: Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1995:126.
50. Groll AH, Walsh TJ. Potential new antifungal agents. Curr Opin Infect Dis 1997;10:449-458.
51. Patterson BE, Coates PE. UK-109,946, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: pharmacokinetics in man. In: Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1995:125.
52. Jezequel SG, Clark M, Evans K et al. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: disposition in animals. In: Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1995:126.
53. Patterson BE, Coates PE, Jezequel SG. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: disposition in man. In: Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1995:126.
54. Denning D, de Favero A, Gluckman E et al. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: clinical efficacy in invasive aspergillosis. In: Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1995:126.
55. Koltin Y, Hitchcock CA. Progress in the search for new triazole antifungal agents. Curr Opin Chem Biol 1997;1:176-182.
56. Dupont B, Denning D, Lode H et al. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: clinical efficacy in chronic invasive aspergillosis. In: Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1995:126.
57. Hegener P, Troke PF, Fakenheuer G et al. Treatment of fluconazole-resistant candidiasis with voriconazole in patients with AIDS. AIDS 1998;12:2227-2228.
58. Girmenia C, Luzi G, Monaco M et al. Use of voriconazole in treatment of Scedosporium apisospermum infection: case report. J Clin Microbiol 1998;36:1436-1438.
59. Schwartz S, Milatovic D, Thiel E. Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukemia. Br J Haematol 1997;97:663-665.
60. Law D, Moore CB, Denning DW. Activity of Sch 56592 compared with those of fluconazole and itraconazole against Candida spp. Antimicrob Agents Chemother 1997;41:2310-2311.
61. Pfaller MA, Messer S, Jonew RN. Activity of a new triazole, posaconazole, compared of four other antifungal agents tested against clinical isolates of Candida spp. and Saccaromyces cervisiae. Antimicrob Agents Chemother 1997;34:1648-1654.
62. Galgiani JN, Lewis ML. In vitro studies of activities of the antifungal triazoles Sch 56592 and itraconazole against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts. Antimicrob Agents Chemother 1997;41:180-183.
63. Perfect JR, Cox GM, Dodge RK et al. In vitro and in vivo efficacies of the azole Sch 56592 against Cryptococcus neoformans. Antimicrob Agents Chemother 1996;40:1910-1913.
64. Oakley KL, Moore CB, Denning DW. In vitro activity of Sch 56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus spp. Antimicrob Agents Chemother 1997;41:1504-1507.
65. Espinel-Ingroff A. Comparison of in vitro activities of the new triazole posaconazole and the echinocandins MK 0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 1998;36:2950-2956.
66. Cacciapuoti A, Parmegiani R, Lobenberg D et al. Efficacy of Sch56592 in pulmonary aspergillosis and candidiasis in mice. In: Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology. 1995:124.
67. Cacciapuoti A, Lobenberg D, Frank D et al. Effect of delayed or extensive treatment with Sch56592 or concomitant treatment with amphotericin B in murine models of pulmonary aspergillosis and systemic candidiasis. In: Program and Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1996:116.
68. Cole GT, Seshan KR, Lobenberg D et al. Evaluation of Sch56592 in clearance of mucosal candidiasis from mice with retroviral-induced immunodeficiency. In: Program and Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1996:116.
69. Parmegiani R, Cacciapuoti A, Lobenberg D et al. Efficacy of Sch56592 in topical infection models. In: Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1995:124.
70. Graybill JR, Bocanegra R, Najvar LK et al. Sch56592 treatment of murine invasive aspergillosis. J Antimicrob Chemother 1998;42:539-542.
71. Oakley KL, Morrissey G, Denning DW. Efficacy of Sch56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus. Antimicrob Agents Chemother 1997;41:1504-1507.
72. Connolly P, Wheat J, Schizlein-Bick C et al. Comparison of a new triazole antifungal agent, Schering 56592, with itraconazole and amphotericin B for treatment of histoplasmosis in immunocompetent mice. Antimicrob Agents Chemother 1999;43:322-328.
73. Sugar AM, Liu XP. In vitro and in vivo activities of Sch56592 against Blastomyces dermatitidis. Antimicrob Agents Chemother 1996;40:1314-1316.
74. Lutz JE, Clemons KV, Aristizabal BH et al. Activity of the triazole Sch56592 against disseminated murine coccidiodomycosis. Antimicrob Agents Chemother 1997;41:1558-1561.
75. Nomeir A, Kumari P, Hubert MJ et al. Comparative pharmacokinetics of a new triazole antifungal agent of Sch56592 in mice, rat, rabbits, dogs and cynomolgus monkeys. In: Program and Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1996:124.
76. Nomeir A, Kumari P, Hubert MJ et al. Bioavailability of Sch56592, a broad spectrum triazole antifungal agent from various formulations. In: Program and Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1996:117.
77. Fung-Tomc JC, Huczko E, Minassian B et al. In vitro activity of a new oral triazole, BMS-207147 (ER-30346). Antimicrob Agents Chemother 1998;42:313-318.
78. Hata K, Kimura J, Miki H. In vitro and vivo antifungal activities of ER-30346, a novel oral triazole with a broad spectrum antifungal spectrum. Antimicrob Agents Chemother 1996;40:2237-2242.
79. Hata K, Kimura J, Miki H et al. Efficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of aspergillosis, candidiasis, and cryptococcosis. Antimicrob Agents Chemother 1996;40:2243-2247.
80. Shock K, Marino S, Baumgartner T et al. Efficacy of a new triazole, BMS-207147, in a model of invasive aspergillosis in immunosuppressed, neutropenic rabbits. In: Final Program Presentation Summaries Abstracts of the 9th Focus on Fungal Infections. San Diego, CA, 1999.
81. Nakamura T, Sakai J, Sonoda T et al. ER 30346, a novel antifungal triazole. IV. Pharmacokinetic and toxicological studies in mice, rats, and dogs. Abstract F94. In: Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1995:129.
82. Metha RT, Hopfer, RL, Gunner LA et al. Formulation, toxicity, and antifungal activity in vitro of liposome-encapsulated nystatin as therapeutic agent for systemic candidiasis. Antimicrob Agents Chemother 1987;31:1897-1900.
83. Metha RT, Hopfer RL, McQueen T et al. Toxicity and therapeutic effects in mice of liposome-encapsulated nystatin for systemic fungal infections. Antimicrob Agents Chemother 1987;31:1901-1903.
84. Wallace TL, Paetznick V, Cossum PA et al. Activity of liposomal nystatin against disseminated Aspergillus fumigatus infection in neutropenic mice. Antimicrob Agents Chemother 1997;41:2238-2243.
85. Rolston K, Baird I, Graham DR et al. Treatment of refractory candidemia in non-neutropenic patients with liposomal nystatin (Nyotran™). In: Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:LB-1.
86. Gordon D, Baird I, Darouiche R et al. Liposomal nystatin vs amphotericin B for candidemia in non-neutropenic patients: a historic comparison. In: Program and Abstracts of the 35th Meeting of the Infectious Disease Society of America. Arlington, VA: Infectious Disease Society of America, 1997;98a.
87. Groll AH, Gonzalez CE, Giri N et al. Liposomal nystatin against experimental pulmonary aspergillosis in persistently neutropenic rabbits: efficacy, safety and non-compartmental pharmacokinetics. J Antimicrob Chemother 1999;43:95-103.
88. Groll AH. Phase-I study of maximum tolerated dose of intravenous liposomal nystatin for the treatment of refractory febrile neutropenia in patients with hematological malignancies. In: Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1995:LB-1.
89. Boutati EI, Maltezou HC, Lopez-Berestein G et al. Phase I study of maximum tolerated dose of intravenous liposomal nystatin for the treatment of refractory febrile neutropenia in patients with hematological malignancies. In: Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1995:LB-1.
90. Walsh TJ, Giri N. Pradimicins: a novel class of broad -spectrum antifungal compounds. Eur J Clin Microbiol Infect Dis 1997;16:93-97.
91. Sawada Y, Numata K, Murakami T et al. Calcium-dependent anticandidal action of pradimicin A. J Antibiot (Tokyo) 1990;43:715-721.
92. Fung-Tomc JC, Minassian B, Huczko E et al. In vitro antifungal and fungicidal spectra of a new pradimicin derivative, BMS-181184. Antimicrob Agents Chemother 1995;39:295-300.
93. Watanabe M, Hiratani T, Uchida K et al. The in-vitro activity of an antifungal antibiotic benamomicin A in comparison with amphotericin B. J Antimicrob Chemother 1996;38:1073-1077.
94. Wardle HM, Law D, Denning DW. In vitro activity of BMS-181184 compared with those of fluconazole and amphotericin B against various Candida species. Antimicrob Agents Chemother 1996;40:2229-2231.
95. Groll AH, Sein T, Peitraitis V et al. Compartmental pharmacokinetics and tissue drug distribution of the pradimicin derivative BMS 181184 in rabbits. Antimicrob Agents Chemother 1998;42:2700-2705.
96. Restrepo MI, Najvar LK, Fothergill AW et al. Pradimicin therapy of disseminated Candida tropicalis infection in the mouse. Med Mycol 1998;36:181-184.
97. Gonzalez CE, Groll AH, Giri N et al. Antifungal activity of the pradimicin derivative BMS 181184 in the treatment of experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother 1998;42:2399-2404.
98. Debono M, Gordee RS. Antibiotics that inhibit fungal cell wall development. Annu Rev Microbiol 1994;48:471-497.
99. Current WL, Tang J, Boylan C et al. Glucan biosynthesis as a target for antifungal therapy: the echinocandin class of antifungal agents. In: Dixon GK, Copping LG, Hollomon DW, eds. Antifungal Agents: Discovery and Mode. Oxford, UK: BIOS Scientific Publishers Ltd., 1995:143-60.
100. Denning DW. Echinocandins and pneumocandins - a new antifungal class with a novel mode of action. J Antimicrob Chemother 1997;40:611-614.
101. Hector FR. Compounds active against cell walls of medically important fungi. Clin Microbiol Rev 1993;6:1-21.
102. Pfaller MA, Messer SA, Coffman S. In vitro susceptibilities of clinical yeasts isolates to a new echinocandin derivative, LY 303366, and other antifungal agents. Antimicrob Agents Chemother 1997;41:763-766.
103. Pfaller MA, Macro F, Messer SA et al. In vitro activity of two echinocandin derivatives, LY 303366 and MK 0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagn Microbiol Infect Dis 1998;30:251-255.
104. Zhanel GG, Karlowsky JA, Harding GA et al. In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species. Antimicrob Agents Chemother 1997;41:863-865.
105. Zhanel GG, Karlowsky JA, Zelenitsky SA et al. Susceptibility of Candida species isolated from the lower gastrointestinal tracts of high-risk patients to the new semisynthetic echinocandin LY 303366 and other anti-fungal agents. Antimicrob Agents Chemother 1998;42:2446-2448.
106. Oakley KL, Moore CB, Denning DW. In vitro activity of the echinocandin antifungal agent LY 303,366 in comparison with itraconazole and amphotericin B against Aspergillus spp. Antimicrob Agents Chemother 1998;42:2726-2730.
107. Krishnarao TV, Galgianin JN. Comparison of the in vitro activities of the echinocandin LY 303366, the pneumocandin MK 0991, and fluconazole against Candida species and Cryptococcus neoformans. Antimicrob Agents Chemother 1997;41:1957-1960.
108. Karlowsky JA, Harding GA, Zelenitsky SA et al. In vitro kill curves of a new semisynthetic echinocandin, LY-303366, against fluconazole-sensitive and -resistant Candida species. Antimicrob Agents Chemother 1997;41:2576-2578.
109. Current WL, Boylan CJ, Rabb PP. Anti-pneumocystis activity of LY 303366 and other echinocandin B analogues. In: Program and Abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1993:186.
110. Zeckner D, Butler T, Boylan C et al. In vitro evaluation of LY303366 against Candida species clinical isolates and evaluation of efficacy in a murine model of systemic candidiasis. In: Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1995:130.
111. Rabb P, Zeckner D, Boylan C et al. LY303366: comparison of activity in murine models of Aspergillus fumigatus infection. In: Program and Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1994:252.
112. Zeckner D, Butler T, Boylan C et al. LY303366 activity against systemic aspergillosis and histoplasmosis in murine models. In: Program and Abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1993:186.
113. Zeckner D, Butler T, Boylan C et al. LY303366 in a rat mucocutaneous vaginal candidiasis model. In: Program and Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1994:252.
114. Zeckner D, Butler T, Boylan C et al. LY303366 activity in a murine systemic candidiasis model. In: Program and Abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1993;186:365a.
115. Petraitis V, Petratienes R, Groll A et al. Antifungal efficacy, safety, and single dose plasma pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother 1998;42:2898-2905.
116. Petraitiene R, Petraitis V, Groll A et al. Antifungal efficacy, safety, and single dose plasma pharmacokinetics of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in persistently neutropenic rabbits. Antimicrob Agents Chemother 1999;43:2148-2155.
117. Verweij PE, Oakley KL, Morrissey J et al. Efficacy of LY 303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosis. Antimicrob Agents Chemother 1998;42:873-878.
118. Groll AH, Mickiene D, Petraitiene R et al. Noncompartmental single-dose plasma pharmacokinetics of the novel echinocandin LY303366 in rabbits. A novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits. In: Program and Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology. 1998:468.
119. Lucas R, Desante K, Hatcher B et al. LY 303366 single dose pharmacokinetics and safety in healthy male volunteers. In: Program and Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1996;F50:108a.
120. Macro F, Pfflaler MA, Messer SA et al. Activity of MK 0991 (L-743-872), a new echinocandin, compared with those of LY 303366 and four other antifungal agents tested against blood stream isolates of Candida spp. Diagn Microbiol Infect Dis 1998;32:33-37.
121. Bartizal K, Gill CJ, Abruzzo GK et al. In vitro preclinical evaluation studies with the echinocandin antifungal MK 0991 (L-743-872). Antimicrob Agents Chemother 1997;41:2326-2332.
122. Vazquez JA, Lynch M, Boikov D et al. In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species. Antimicrob Agents Chemother 1997;41:1612-1614.
123. Franzot SP, Casadevall A. Pneumocandin L-743-872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro. Antimicrob Agents Chemother 1997;41:2331-2336.
124. Graybill JR, Najvar LK, Luther MF et al. Treatment of murine disseminated candidiasis with L-743872. Antimicrob Agents Chemother 1997;41:1775-1777.
125. Abruzzo GK, Flattery AM, Gill CJ et al. Evaluation of the echinocandin antifungal MK 0991 (L-743-872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob Agents Chemother 1997;41:2333-2338.
126. Smith JG, Abruzzo GK, Gill CJ et al. Evaluation of pneumocandin L-743872 in neutropenic mouse models of disseminated candidiasis and aspergillosis. In: Program and Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1996;F41:107a.
127. Bartizal K, Smith JG, Gill CJ et al. Preclinical efficacy of MK 0991 in pancytopenic mouse models of disseminated candidiasis and aspergillosis. In: Program and Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1997;F80:159a.
128. Graybill JR, Najvar LK, Montalbo EM et al. Treatment of histoplasmosis with MK 0991 (L-743,872). Antimicrob Agents Chemother 1998;42:151-153.
129. Powles MA, Liberator P, Anderson J et al. Efficacy of MK-991 (L-743-872), a semisynthetic pneumocandin, in murine models of Pneumocystis carinii. Antimicrob Agents Chemother 1998;42:1985-1989.
130. Hajdu R, Thompson R, Sundelof JG et al. Preliminary animal pharmacokinetics of the parenteral antifungal agent MK 0991 (L-743,872). Antimicrob Agents Chemother 1997;41:2339-2344.
131. Stone JA, Holland SD, Ju WD et al. Single and multiple dose pharmacokinetics of the antifungal agent MK 0991 in man. In: Program and Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:C51.
132. Arathoon E, Gotuzzo E, Noriega L et al. A randomized, double-blind, multicenter trial of MK-0991, an echinocandin antifungal agent, vs amphotericin B for the treatment (Tx) of oropharyngeal (OPC) and esophageal (EC) candidiasis in adults. Denver CO: Infect Dis Soc Am, 1998.
133. Petratis V, Petraitiene R, Leguit RJ et al. Combination antifungal therapy with FK463 plus amphotericin B in treatment of experimental pulmonary aspergillosis. In: Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1999:581.
134. Matsumoto S, Wakai Y, Maki K et al. Efficacy of FK 463, a novel water-soluble echinocandin-like lipopeptide in murine models of disseminated candidiasis. In: Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:142.
135. Wakai Y, Matsumoto S, Maki K et al. Efficacy of FK 463, a novel water-soluble echinocandin-like lipopeptide in murine models of pulmonary aspergillosis. In: Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:143.
136. Suzuki S, Terakawa M, Yokobayashi F et al. Pharmacokinetics of FK 463, a novel water-soluble echinocandin-like lipopeptide in animals. In: Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:144.
137. Azuma J, Yamamoto I, Ogura M et al. Phase I study of FK 463, new antifungal agent, in healthy adult male volunteers. In: Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1998:146.
138. Hector RF, Zimmer BL, Pappagianis D. Evaluation of nikkomycin X and Z in murine models of coccidiodomycosis, histoplasmosis, and blastomycosis. Antimicrob Agents Chemother 1990;34:587-593.
139. Graybill JR, Najvar LK, Bocanegra R et al. Efficacy of nikkomycin Z in the treatment of murine histoplasmosis. Antimicrob Agents Chemother 1998;42:2371-2374.
140. Clemons KV, Stevens DA. Efficacy of nikkomycin Z against experimental pulmonary blastomycosis. Antimicrob Agents Chemother 1997;41:2026-2028.
141. Hector RF, Braun PC. Synergistic action of nikkomycin X and Z with papulacandin B on whole cells and regenerating proptoplasts of Candida albicans. Antimicrob Agents Chemother 1986;29:389-394.
142. Hector RF, Schaller K. Positive interaction of nikkomycins and azoles against Candida albicans in vitro and in vivo. Antimicrob Agents Chemother 1992;36:1284-1289.
143. Milewski S, Mignini F, Borowski E. Synergistic action of nikkomycin X/Z with azole antifungals on Candida albicans. J Gen Microbiol 1991;137:2155-2161.
144. Gooday GW. The potential of novel antifungal drugs for the treatment of disease in immunocompromised host. Exp Opin Invest Drugs 1995;4:679-691.
145. Dominguez JM, Kelly VA, Kinsman OS et al. Sordarins: a new class of antifungals with inhibition of the protein synthesis elongation cycle in yeasts. Antimicrob Agents Chemother 1998;42:2274-2278.
146. Herreris E, Martinez CM, Almela MJ et al. Sordarins: in vitro activities of new antifungal derivatives against pathogenic yeasts, Pneumocystis carinii, and filamentous fungi. Antimicrob Agents Chemother 1998;42:2863-2869.
147. Joly V, Saint-Julien L, Carbon C et al. In vivo activity of interferon γ in combination with amphotericin B in the treatment of experimental cryptococcosis. J Infect Dis 1994;170:1331-1334.
148. Graybill JR, Bocanegra R, Luther M. Antifungal combination therapy with granulocyte colony-stimulating factor and fluconazole in experimental disseminated candidiasis. Eur J Clin Microbiol Infect Dis 1995;14:700-703.
149. Vora S, Purimetla N, Brummer E et al. Activity of voriconazole, a new triazole, combined with neutrophils or monocytes against Candida albicans: effect of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. Antimicrob Agents Chemother 1998;42:907-910.
150. Graybill JR, Bocanegra R, Najvar LK et al. Granulocyte colony-stimulating factor and azole antifungal therapy in murine aspergillosis: role of immune suppression. Antimicrob Agents Chemother 1998;42:2467-2473.